Kyverna Therapeutics (KYTX) announced positive interim data from the Phase 2 portion of the registrational KYSA-6 clinical trial of KYV-101 in generalized myasthenia gravis, or gMG. The data will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback